Microvolume UV-Vis patent awarded for innovations by DeNovix

DeNovix Inc., a developer and manufacturer of life science instrumentation and assays, today announces the granting of US patent 9,442,009 associated with instrumentation to improve the accuracy and reliability of microvolume spectrophotometry.

The patent, “Apparatus and Method for Making Optical Measurements of Samples” recognizes and protects DeNovix’ novel opto-mechanical design.

The patented design, combined with proprietary measurement algorithms developed by DeNovix application scientists and engineers, delivers greatly improved accuracy of pathlength determination and increased sensitivity over existing techniques.

The innovations in this patent are some of the key advances that make our DS-11 Series the most sensitive and reliable microvolume UV-Vis spectrophotometer available,”

“We are delighted that the USPTO has recognized the novelty of our design and the work of our team.”

Fred Kielhorn, CEO of DeNovix.

“The ability to set measurement pathlengths with such precise control and long-term reproducibility is one of the core innovations that DeNovix has brought to the market. We reinvented the microvolume measurement process to deliver a system that is calibration-free and delivers industry-leading lower and upper detection limits. The dynamic range is truly best-in-class,” stated Kielhorn.

The DeNovix DS-11 FX+ combines patented and patent pending absorbance and fluorescence technologies to deliver the most flexible and complete system available for nucleic acid and protein quantification.

DeNovix SmartPath® Technology enables rapid and accurate 1 µL UV-Vis quantification over an industry-leading dynamic range of 0.75 ng/µL dsDNA to 37500 ng/µL.

The addition of fluorescence also enables researchers to measure picogram concentrations of sample with increased specificity in one compact instrument.

The DS-11 Series features full Wi-Fi, USB, and Ethernet connectivity allowing users to easily export data via email, a USB drive, to network drives or network printers, or print cryotube labels with an optional printer.

Measurements are made using DeNovix’ highly rated, custom Android™ operating system and a stunning, high-resolution, glove-compatible touch screen.

Intuitive EasyApps® software featuring pre-configured and custom applications make the DS-11 Series easy to use as well as powerful and flexible.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DeNovix Inc.. (2021, October 29). Microvolume UV-Vis patent awarded for innovations by DeNovix. News-Medical. Retrieved on December 27, 2024 from https://www.news-medical.net/news/20160929/Microvolume-UV-Vis-patent-awarded-for-innovations-by-DeNovix.aspx.

  • MLA

    DeNovix Inc.. "Microvolume UV-Vis patent awarded for innovations by DeNovix". News-Medical. 27 December 2024. <https://www.news-medical.net/news/20160929/Microvolume-UV-Vis-patent-awarded-for-innovations-by-DeNovix.aspx>.

  • Chicago

    DeNovix Inc.. "Microvolume UV-Vis patent awarded for innovations by DeNovix". News-Medical. https://www.news-medical.net/news/20160929/Microvolume-UV-Vis-patent-awarded-for-innovations-by-DeNovix.aspx. (accessed December 27, 2024).

  • Harvard

    DeNovix Inc.. 2021. Microvolume UV-Vis patent awarded for innovations by DeNovix. News-Medical, viewed 27 December 2024, https://www.news-medical.net/news/20160929/Microvolume-UV-Vis-patent-awarded-for-innovations-by-DeNovix.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DeNovix CellDrop Becomes First ACT® Label Certified Automated Cell Counter